A research agreement between IPSEN and AGV Discovery
AGV Discovery has entered into a collaboration with the major pharmaceutical company IPSEN for the development of its ERK inhibitor candidates. MAPK pathway represents a promising target as one of the most commonly mutated oncogenic driver pathways in cancers with high unmet medical needs.
